Pliant Therapeutics/$PLRX
1D1W1MYTD1Y5YMAX
Capital at risk
About Pliant Therapeutics
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
- Ticker
- $PLRX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 49
- Headquarters
- South San Francisco, United States
- Website
- pliantrx.com
PLRX Metrics
BasicAdvanced
$67M
-
-$1.50
1.27
-
Price and volume
Market cap
$67M
Beta
1.27
52-week high
$1.95
52-week low
$1.02
Average daily volume
426K
Financial strength
Current ratio
9.897
Quick ratio
9.644
Long term debt to equity
0.18
Total debt to equity
0.196
Interest coverage (TTM)
-95.88%
Profitability
EBITDA (TTM)
-89.866
Management effectiveness
Return on assets (TTM)
-23.27%
Return on equity (TTM)
-50.29%
Valuation
Price to book
0.46
Price to tangible book (TTM)
0.46
Price to free cash flow (TTM)
-0.939
Free cash flow yield (TTM)
-106.49%
Free cash flow per share (TTM)
-1.15
Growth
Earnings per share change (TTM)
-55.84%
3-year earnings per share growth (CAGR)
-18.22%
What the Analysts think about PLRX
Analyst ratings (Buy, Hold, Sell) for Pliant Therapeutics stock.
Analyst projections of the future price of Pliant Therapeutics stock.
PLRX Financial Performance
Revenues and expenses
PLRX Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.